37 results on '"Pei, Lixia"'
Search Results
2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
3. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
4. Electronic effects of amine-imine nickel and palladium catalysts on ethylene (co)polymerization
5. Microneedle-based interstitial fluid extraction for drug analysis: Advances, challenges, and prospects
6. Cholesterol and Phospholipid-free Multilamellar Niosomes Regulate Transdermal Permeation of a Hydrophobic Agent Potentially Administrated for Treating Diseases in Deep Hair Follicles
7. Acid-responsive PEGylated branching PLGA nanoparticles integrated into dissolving microneedles enhance local treatment of arthritis
8. Keratinocyte membrane-mediated nanodelivery system with dissolving microneedles for targeted therapy of skin diseases
9. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
10. Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer
11. Bidirectional association between irritable bowel syndrome and restless legs syndrome: a systematic review and meta-analysis
12. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
13. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
14. MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
15. Preparation and properties of Ag-coated activated carbon nanocomposites for indoor air quality control
16. Bis(β-ketoamino) copper complexes for vinyl polymerization of norbornene: Correlation between precursor structure and catalytic activity
17. Anti-tumor potential of ethanol extract of Curcuma phaeocaulis Valeton against breast cancer cells
18. P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma
19. Effect of Mg-based spherical quasicrystals on microstructure and mechanical properties of AZ91 alloys
20. Vinyl polymerization of norbornene with nickel catalysts bearing [ N, N] six-membered chelate ring: Important influence of ligand structure on activity
21. Low Breakage and Size-controlled Preparation of NiCl 2 Immobilized Hollow Polyurea Microcapsules
22. Preparation of Well-shaped Microcapsule Immobilizing Inorganic Nanoparticles
23. Drastic ligand electronic effect on anilido–imino nickel catalysts toward ethylene polymerization
24. Styrene polymerization with novel anilido–imino nickel complexes/MAO catalytic system: Catalytic behavior, microstructure of polystyrene and polymerization mechanism
25. MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
26. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
27. MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
28. P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
29. P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
30. P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
31. OAB-054: Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma
32. Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
33. Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA
34. Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002
35. Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study
36. Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)
37. Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.